Humoral and cell-mediated immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with cancer on active treatment: Focus on wild type, Delta and Omicron strains

• Published in: Journal of clinical oncology Vol. 40; no. 16_suppl; p. e13505
• Main Authors: Lasagna, Angioletta, Cassaniti, Irene, Bergami, Federica, Lilleri, Daniele, Percivalle, Elena, Quaccini, Mattia, Alessio, Niccolò, Comolli, Giuditta, Sarasini, Antonella, Camilla, Josè, Ferrari, Alessandro, Arena, Francesca, Secondino, Simona, Cicognini, Daniela, Schiavo, Roberta, Lo Cascio, Giuliana, Cavanna, Luigi, Baldanti, Fausto, Pedrazzoli, Paolo
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 01.06.2022

e13505Background: Although a full course of COVID-19 vaccine is effective in cancer patients, the duration of the protection and the efficacy of a booster dose against the new variants remain unknown. We prospectively evaluated the immunogenicity of the third dose of the SARS-CoV-2 BNT162b2 mRNA vac...